Indication · with rvo with up to every 8-week dosing

with rvo with up to every 8-week dosing FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T112050ZBuilt

We track 1 with rvo with up to every 8-week dosing drug. 1 FDA approval recorded, most recently Eylea® on Nov 2025.

Drugs

DrugSponsorModalityDesignations
Eylea®REGN——

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
Nov 2025Month disclosedEylea®REGNFDA approvalwith RVO with up to every 8-week dosingApprovedSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What with rvo with up to every 8-week dosing drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.